vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 2.2%, a 11.1% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $1.1M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -3.3%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
AMPH vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $200.5M |
| Net Profit | $24.4M | $4.5M |
| Gross Margin | 46.8% | 32.2% |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 2.2% |
| Revenue YoY | -1.8% | 5.2% |
| Net Profit YoY | -35.7% | 421.4% |
| EPS (diluted) | $0.51 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $183.1M | $201.5M | ||
| Q3 25 | $191.8M | $216.0M | ||
| Q2 25 | $174.4M | $202.8M | ||
| Q1 25 | $170.5M | $190.5M | ||
| Q4 24 | $186.5M | $192.2M | ||
| Q3 24 | $191.2M | $210.3M | ||
| Q2 24 | $182.4M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $24.4M | $4.6M | ||
| Q3 25 | $17.4M | $8.6M | ||
| Q2 25 | $31.0M | $-73.6M | ||
| Q1 25 | $25.3M | $-1.4M | ||
| Q4 24 | $38.0M | $-500.0K | ||
| Q3 24 | $40.4M | $10.7M | ||
| Q2 24 | $37.9M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 46.8% | 31.5% | ||
| Q3 25 | 51.4% | 33.5% | ||
| Q2 25 | 49.6% | 31.6% | ||
| Q1 25 | 50.0% | 29.9% | ||
| Q4 24 | 46.5% | 32.1% | ||
| Q3 24 | 53.3% | 35.2% | ||
| Q2 24 | 52.2% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 3.5% | ||
| Q3 25 | 13.2% | 7.3% | ||
| Q2 25 | 24.2% | -33.3% | ||
| Q1 25 | 21.9% | -0.2% | ||
| Q4 24 | 24.2% | -6.6% | ||
| Q3 24 | 29.8% | 6.9% | ||
| Q2 24 | 30.3% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 13.3% | 2.3% | ||
| Q3 25 | 9.0% | 4.0% | ||
| Q2 25 | 17.8% | -36.3% | ||
| Q1 25 | 14.8% | -0.7% | ||
| Q4 24 | 20.4% | -0.3% | ||
| Q3 24 | 21.1% | 5.1% | ||
| Q2 24 | 20.8% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.51 | $0.20 | ||
| Q3 25 | $0.37 | $0.48 | ||
| Q2 25 | $0.64 | $-4.00 | ||
| Q1 25 | $0.51 | $-0.08 | ||
| Q4 24 | $0.74 | $-0.04 | ||
| Q3 24 | $0.78 | $0.58 | ||
| Q2 24 | $0.73 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $195.8M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.2B |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $282.8M | $197.0M | ||
| Q3 25 | $276.2M | $167.8M | ||
| Q2 25 | $231.8M | $157.2M | ||
| Q1 25 | $236.9M | $175.6M | ||
| Q4 24 | $221.6M | $159.8M | ||
| Q3 24 | $250.5M | $146.4M | ||
| Q2 24 | $217.8M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $788.8M | $1.2B | ||
| Q3 25 | $776.7M | $1.2B | ||
| Q2 25 | $757.5M | $1.2B | ||
| Q1 25 | $751.3M | $1.3B | ||
| Q4 24 | $732.3M | $1.3B | ||
| Q3 24 | $727.7M | $1.3B | ||
| Q2 24 | $713.3M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $5.8M |
| Free Cash FlowOCF − Capex | $24.6M | $1.1M |
| FCF MarginFCF / Revenue | 13.4% | 0.5% |
| Capex IntensityCapex / Revenue | 4.5% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $32.9M | $46.9M | ||
| Q3 25 | $52.6M | $28.9M | ||
| Q2 25 | $35.6M | $13.7M | ||
| Q1 25 | $35.1M | $11.7M | ||
| Q4 24 | $29.0M | $33.7M | ||
| Q3 24 | $60.0M | $42.4M | ||
| Q2 24 | $69.1M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $24.6M | $42.2M | ||
| Q3 25 | $47.2M | $21.2M | ||
| Q2 25 | $25.0M | $5.6M | ||
| Q1 25 | $24.4M | $2.1M | ||
| Q4 24 | $16.6M | $18.3M | ||
| Q3 24 | $46.2M | $25.2M | ||
| Q2 24 | $63.1M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 13.4% | 20.9% | ||
| Q3 25 | 24.6% | 9.8% | ||
| Q2 25 | 14.3% | 2.8% | ||
| Q1 25 | 14.3% | 1.1% | ||
| Q4 24 | 8.9% | 9.5% | ||
| Q3 24 | 24.1% | 12.0% | ||
| Q2 24 | 34.6% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 4.5% | 2.3% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 4.0% | ||
| Q1 25 | 6.3% | 5.0% | ||
| Q4 24 | 6.7% | 8.0% | ||
| Q3 24 | 7.2% | 8.2% | ||
| Q2 24 | 3.3% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.35× | 10.20× | ||
| Q3 25 | 3.03× | 3.36× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 3.96× | ||
| Q2 24 | 1.82× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ROG
Segment breakdown not available.
